Titan Pharmaceuticals receives Nasdaq notice of non-compliance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2024
0mins
Should l Buy ?
Compliance Issue: Titan Pharmaceuticals received a notice from Nasdaq indicating it is not in compliance with listing requirements due to the late filing of its Q3 Form 10-Q for the quarter ended September 30.
Action Plan: The company is working to file the report promptly and must submit a plan by January 21, 2025, if the filing is not completed by that date.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
